Brooklyn FI LLC Acquires New Position in Agilent Technologies, Inc. (NYSE:A)

Brooklyn FI LLC bought a new position in shares of Agilent Technologies, Inc. (NYSE:A) during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor bought 42,496 shares of the medical research company’s stock, valued at approximately $5,822,000.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in the stock. CKW Financial Group increased its position in shares of Agilent Technologies by 114.9% in the fourth quarter. CKW Financial Group now owns 187 shares of the medical research company’s stock valued at $25,000 after buying an additional 100 shares in the last quarter. Global X Japan Co. Ltd. raised its position in Agilent Technologies by 161.1% during the fourth quarter. Global X Japan Co. Ltd. now owns 188 shares of the medical research company’s stock worth $25,000 after acquiring an additional 116 shares during the last quarter. Hanson & Doremus Investment Management lifted its holdings in shares of Agilent Technologies by 66.5% in the fourth quarter. Hanson & Doremus Investment Management now owns 263 shares of the medical research company’s stock valued at $35,000 after purchasing an additional 105 shares in the last quarter. OFI Invest Asset Management acquired a new stake in shares of Agilent Technologies in the fourth quarter valued at approximately $37,000. Finally, RPg Family Wealth Advisory LLC purchased a new position in shares of Agilent Technologies during the 3rd quarter worth approximately $38,000.

Analyst Ratings Changes

Several equities analysts have weighed in on A shares. Citigroup raised their price target on Agilent Technologies to $165.00 and gave the stock a “buy” rating in a research report on Thursday, December 19th. Bank of America dropped their price objective on Agilent Technologies from $153.00 to $150.00 and set a “neutral” rating for the company in a research report on Friday, December 13th. JPMorgan Chase & Co. reduced their target price on shares of Agilent Technologies from $165.00 to $160.00 and set an “overweight” rating on the stock in a report on Tuesday, November 26th. Robert W. Baird lowered their price target on shares of Agilent Technologies from $161.00 to $159.00 and set an “outperform” rating for the company in a report on Thursday, February 27th. Finally, Sanford C. Bernstein reduced their price objective on shares of Agilent Technologies from $140.00 to $135.00 and set a “market perform” rating on the stock in a research note on Tuesday, November 26th. Seven equities research analysts have rated the stock with a hold rating and eight have assigned a buy rating to the stock. According to data from MarketBeat.com, Agilent Technologies currently has a consensus rating of “Moderate Buy” and a consensus target price of $146.15.

Insiders Place Their Bets

In other Agilent Technologies news, CEO Padraig Mcdonnell sold 1,911 shares of the business’s stock in a transaction dated Tuesday, January 21st. The stock was sold at an average price of $150.00, for a total transaction of $286,650.00. Following the transaction, the chief executive officer now owns 39,652 shares in the company, valued at $5,947,800. The trade was a 4.60 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, VP Rodney Gonsalves sold 1,908 shares of the stock in a transaction dated Monday, March 17th. The shares were sold at an average price of $121.98, for a total value of $232,737.84. Following the completion of the sale, the vice president now owns 21,786 shares of the company’s stock, valued at approximately $2,657,456.28. This trade represents a 8.05 % decrease in their position. The disclosure for this sale can be found here.

Agilent Technologies Stock Up 0.5 %

Shares of NYSE A opened at $123.10 on Wednesday. The stock has a market capitalization of $35.09 billion, a PE ratio of 28.30, a P/E/G ratio of 3.44 and a beta of 1.11. The company has a quick ratio of 1.66, a current ratio of 2.20 and a debt-to-equity ratio of 0.56. The firm has a fifty day moving average of $137.70 and a 200-day moving average of $137.68. Agilent Technologies, Inc. has a 52-week low of $117.17 and a 52-week high of $155.35.

Agilent Technologies (NYSE:A) last announced its quarterly earnings results on Wednesday, February 26th. The medical research company reported $1.31 EPS for the quarter, topping the consensus estimate of $1.27 by $0.04. The company had revenue of $1.68 billion during the quarter, compared to analyst estimates of $1.67 billion. Agilent Technologies had a return on equity of 25.56% and a net margin of 19.27%. On average, analysts anticipate that Agilent Technologies, Inc. will post 5.57 EPS for the current year.

Agilent Technologies Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Wednesday, April 23rd. Shareholders of record on Tuesday, April 1st will be given a dividend of $0.248 per share. The ex-dividend date is Tuesday, April 1st. This represents a $0.99 dividend on an annualized basis and a yield of 0.81%. Agilent Technologies’s dividend payout ratio (DPR) is 22.76%.

Agilent Technologies Company Profile

Agilent Technologies, Inc provides application focused solutions to the life sciences, diagnostics, and applied chemical markets worldwide. The company operates in three segments: Life Sciences and Applied Markets, Diagnostics and Genomics, and Agilent CrossLab. The Life Sciences and Applied Markets segment offers liquid chromatography systems and components; liquid chromatography mass spectrometry systems; gas chromatography systems and components; gas chromatography mass spectrometry systems; inductively coupled plasma mass spectrometry instruments; atomic absorption instruments; microwave plasma-atomic emission spectrometry instruments; inductively coupled plasma optical emission spectrometry instruments; raman spectroscopy; cell analysis plate based assays; flow cytometer; real-time cell analyzer; cell imaging systems; microplate reader; laboratory software; information management and analytics; laboratory automation and robotic systems; dissolution testing; and vacuum pumps, and measurement technologies.